Friday, February 10, 2012
Almirall says Sativex is available to health professionals and patients in hospital pharmacies in Spain. It is the first specific treatment for spasticity in Multiple Sclerosis (MS) patients who have not responded adequately to other treatments. Sativex is administered as oromucosal spray enabling flexible dosage, which is particularly appropriate given the variable nature of spasticity and MS itself. It is an endocannabinoid modulator made of two actives: THC (delta-9-tetrahidrocannabinol) and CBD (cannabidiol).